Structure Therapeutics, Inc. Sponsored ADR (GPCR) AI Stock Analysis

• Market Cap: $3.68B
• Dividend Yield: N/A
• Average Volume (3M): 906.47K
• Price to Earnings (P/E): 31.2
• Beta (1Y): 1.25
• Revenue Growth: N/A
• EPS Growth: -64.91%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.17
• Shares Outstanding: 70,841,810
• 10 Day Avg. Volume: 1,004,090
• 30 Day Avg. Volume: 906,471
• PEG Ratio: -11.37
• Price to Book (P/B): 2.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -18.23
• Enterprise Value/Market Cap: 0.57
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -3.07K
• Enterprise Value/Ebitda: -13.37
• 1Y Price Target: $108.34
• Price Target Upside: 108.79% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): -1.72
• Revenue Forecast (FY): $7.14M

• Rating: 56 Neutral
• Price Target: $55.00 ▲(5.99% Upside)
• Action: Reiterated Date: 03/16/26
• Date: Action: Reiterated 03/16/26

The score reflects a strong balance sheet and positive, value-relevant corporate events (Phase 2 obesity results and a $100M licensing deal), partially offset by weak financial performance driven by no revenue and accelerating cash burn, along with bearish technical trends despite oversold indicators.

Positive Factors

Balance Sheet Strength

Minimal leverage and a materially larger equity base provide lasting financial flexibility to fund clinical programs. This reduces near-term refinancing risk, supports Phase 3 costs or selective partnering, and preserves strategic optionality without immediate solvency pressure.

Phase 2 Efficacy & Tolerability

Robust, durable efficacy and class-consistent tolerability position aleniglipron as a potential best-in-class oral GLP-1. This structural clinical success underpins Phase 3 advancement, supports competitive differentiation in obesity therapeutics, and strengthens long-term commercial prospects.

Non-Dilutive Licensing Deal

The $100M upfront plus royalties provides non-dilutive capital and third-party validation of the platform/IP. Partnering with established pharma enhances commercialization optionality, reduces immediate funding pressure, and validates the company’s patent and discovery capabilities long-term.

Negative Factors

Pre-Revenue Business Model

As a clinical-stage biotech with no product revenue, the company must rely on external financing, partnerships, or milestone receipts to fund operations. This structural model increases funding dependency and elongates the timeline to sustainable commercial cash generation.

High Cash Burn

Very large negative operating and free cash flow reflect accelerating spending to advance programs. Persistent high burn materially raises the probability of future financing needs, which can dilute shareholders or force less favorable partnering if clinical plans cost more than expected.

Widening Net Losses

Substantially increasing net losses driven by scaled R&D indicate mounting resource requirements to achieve late‑stage milestones. Over time this trend pressures capital allocation, heightens financing risk, and may constrain investment in other programs unless offset by partnerships or revenues.

Structure Therapeutics, Inc. Sponsored ADR Business Overview & Revenue Model

Company Description

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

How the Company Makes Money

Structure Therapeutics is a clinical-stage biopharmaceutical company and, as such, it has historically not generated significant revenue from product sales; its business model is primarily to invest in research and clinical development of drug candidates with the aim of future commercialization or value realization through partnering. Potential and typical revenue sources for a company at this stage include (i) collaboration or licensing payments from pharmaceutical partners (such as upfront payments, research funding reimbursements, development and regulatory milestone payments, and eventual sales-based royalties if a partnered product reaches the market), and (ii) interest or other income on cash and marketable securities. Specific, current, and material partnership counterparties, deal terms, and the extent of any collaboration-derived revenue are null.

Structure Therapeutics, Inc. Sponsored ADR Financial Statement Overview

Summary

Mixed development-stage profile: income statement and cash flow are pressured by $0 revenue and widening losses with deeply negative operating/free cash flow, but the balance sheet is strong with minimal leverage and substantially higher equity, supporting near-term solvency.

Income Statement

The company is still pre-revenue (revenue is $0 across all reported years), so results are driven by operating spend rather than commercial execution. Losses have widened over time, with net loss increasing from about $40.0M (2021) to about $141.2M (2025), indicating a rising cash burn profile as R&D scales. While this trajectory can be normal for biotech, the lack of revenue and expanding losses weigh heavily on income-statement quality and near-term profitability.

Balance Sheet

The balance sheet is a clear strength: leverage is minimal, with debt staying very low and debt-to-equity around ~0.4% in 2024–2025. Equity has expanded materially (from negative levels in 2020–2022 to ~$1.52B in 2025), suggesting substantial capital raises and improved solvency. The main weakness is that returns remain negative given ongoing losses, but overall financial flexibility appears strong due to low debt and a large equity base.

Cash Flow

Cash generation remains weak, with operating cash flow consistently negative and worsening to about -$222.2M in 2025 (from about -$32.2M in 2021). Free cash flow is also deeply negative (about -$225.8M in 2025), and the year-over-year change in free cash flow has been volatile (including a sharp deterioration in earlier years and a reported improvement in 2025 that still leaves substantial burn). A positive point is that free cash flow broadly tracks net losses (roughly one-to-one), suggesting limited non-cash distortion—but the absolute burn level remains the key risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-3.90M	0.00	0.00	0.00	0.00
EBITDA	-136.79M	-157.24M	-102.48M	-52.28M	-37.62M
Net Income	-141.20M	-122.53M	-89.62M	-51.32M	-40.01M
Balance Sheet
Total Assets	1.58B	903.33M	482.02M	97.84M	111.16M
Cash, Cash Equivalents and Short-Term Investments	1.45B	883.52M	467.32M	90.84M	107.31M
Total Debt	6.49M	3.86M	5.45M	260.00K	621.00K
Total Liabilities	67.54M	38.49M	29.05M	212.99M	175.89M
Stockholders Equity	1.52B	864.84M	452.97M	-115.14M	-64.73M
Cash Flow
Free Cash Flow	-225.81M	-117.93M	-81.66M	-46.27M	-33.37M
Operating Cash Flow	-222.20M	-116.64M	-79.49M	-46.12M	-32.16M
Investing Cash Flow	89.80M	-358.91M	-268.34M	-62.11M	17.86M
Financing Cash Flow	762.52M	515.26M	451.53M	29.01M	103.25M

Structure Therapeutics, Inc. Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 51.89
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GPCR, the sentiment is Negative. The current price of 51.89 is below the 20-day moving average (MA) of 60.84, below the 50-day MA of 72.32, and above the 200-day MA of 40.33, indicating a neutral trend. The MACD of -5.00 indicates Positive momentum. The RSI at 28.10 is Positive, neither overbought nor oversold. The STOCH value of 25.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GPCR.

Structure Therapeutics, Inc. Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	61 Neutral	$1.83B	―	12.06%	―	1128.17%	―
ZYME	59 Neutral	$1.74B	―	-26.00%	―	116.21%	43.93%
GPCR	56 Neutral	$3.68B	31.19	-14.55%	―	―	-64.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNDX	51 Neutral	$2.09B	-6.38	-206.62%	―	597.19%	0.45%

Structure Therapeutics, Inc. Sponsored ADR Corporate Events

Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results

On March 16, 2026, Structure Therapeutics reported positive topline results from its Phase 2 ACCESS II trial of aleniglipron, showing statistically significant placebo-adjusted mean weight loss of 16.3% at 180 mg and 16.0% at 240 mg over 44 weeks, with no evidence of a weight-loss plateau. Interim data from the ACCESS open-label extension showed continued weight loss up to 16.2% at 56 weeks with a 120 mg dose, while a separate body composition study and extension data indicated that a lower 2.5 mg starting dose and slower titration meaningfully improved tolerability and kept adverse event–related discontinuations in the low single digits.

Across more than 625 participants, aleniglipron has so far demonstrated a safety profile without drug-induced liver injury, persistent liver enzyme elevations or QTc prolongation, supporting its potential for chronic use in obesity treatment. These outcomes reinforce the drug’s positioning as a potentially best-in-class oral GLP-1 therapy and underpin Structure Therapeutics’ plan to move into Phase 3 trials, with an FDA End-of-Phase 2 meeting scheduled for the second quarter of 2026 and Phase 3 initiation targeted for the second half of 2026.

The most recent analyst rating on (GPCR) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Structure Therapeutics, Inc. Sponsored ADR stock, see the GPCR Stock Forecast page.

Structure Therapeutics inks major GLP-1 licensing deal

On December 30, 2025, Gasherbrum Bio, a subsidiary of Structure Therapeutics, entered into a non-exclusive licensing agreement with Genentech and Roche, granting them rights under certain Gasherbrum patents covering a distinct class of oral GLP-1 receptor agonists to develop and commercialize products containing Genentech’s proprietary compound CT-996. In return, Gasherbrum will receive a one-time $100 million payment within 30 days of signing and low single-digit royalties on net sales of CT-996 products until the relevant patents expire or a specified earlier date, while retaining full control over its own metabolic pipeline, as the license expressly does not encumber Structure’s ongoing programs, including aleniglipron and other GLP-1, dual amylin/calcitonin, and GIPR/GCGR modulators, and preserves Gasherbrum’s ability to terminate the deal in the event of material breach or patent challenges, providing a significant non-dilutive capital infusion without ceding broader strategic or patent prosecution rights.

The most recent analyst rating on (GPCR) stock is a Hold with a $73.00 price target. To see the full list of analyst forecasts on Structure Therapeutics, Inc. Sponsored ADR stock, see the GPCR Stock Forecast page.